Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Schlomm

Showing results (91-100 of 359) with videos related to

Pageof 36
Sort By:
International Journal of Cancer|August 14, 2012
Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancersJulia Müller, Arne Ehlers, Lia Burkhardt, et al.
Urology Case Reports|November 25, 2024
Solitary fibrous tumor of the prostate with accompanying low-grade prostate cancerMarie-Lisa Eich, Kira Furlano, Georg Hilfenhaus, et al.
The Prostate|March 24, 2018
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrenceRaisa S Pompe, Philipp Gild, Pierre I Karakiewicz, et al.
BJU International|May 9, 2017
Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidanceJeffrey J Tosoian, Meera R Chappidi, Jay T Bishoff, et al.
Cancer Research|May 31, 2013
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cellsHarri M Itkonen, Sarah Minner, Ingrid J Guldvik, et al.
Toxins|November 26, 2024
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor InjectionHeinrich Schulte-Baukloh, Apostolos Apostolidis, Catarina Weiss, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|September 27, 2012
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancerAnna Flammiger, Florian Bayer, Ana Cirugeda-Kühnert, et al.
BJU International|November 13, 2021
A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancerSebastian L Hofbauer, Ferdinand Luger, Niklas Harland, et al.
The Prostate|October 7, 2014
Tumor volume in insignificant prostate cancer: increasing threshold gains increasing riskJonas Schiffmann, Judith Connan, Georg Salomon, et al.
Human Pathology|May 7, 2013
Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrenceMaria Christina Tsourlakis, Michael Schoop, Christoph Plass, et al.
Pageof 36

Showing results (91-100 of 359) with videos related to

Sort By:
Pageof 36
International Journal of Cancer|August 14, 2012
Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancersJulia Müller, Arne Ehlers, Lia Burkhardt, et al.
Urology Case Reports|November 25, 2024
Solitary fibrous tumor of the prostate with accompanying low-grade prostate cancerMarie-Lisa Eich, Kira Furlano, Georg Hilfenhaus, et al.
The Prostate|March 24, 2018
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrenceRaisa S Pompe, Philipp Gild, Pierre I Karakiewicz, et al.
BJU International|May 9, 2017
Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidanceJeffrey J Tosoian, Meera R Chappidi, Jay T Bishoff, et al.
Cancer Research|May 31, 2013
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cellsHarri M Itkonen, Sarah Minner, Ingrid J Guldvik, et al.
Toxins|November 26, 2024
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor InjectionHeinrich Schulte-Baukloh, Apostolos Apostolidis, Catarina Weiss, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|September 27, 2012
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancerAnna Flammiger, Florian Bayer, Ana Cirugeda-Kühnert, et al.
BJU International|November 13, 2021
A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancerSebastian L Hofbauer, Ferdinand Luger, Niklas Harland, et al.
The Prostate|October 7, 2014
Tumor volume in insignificant prostate cancer: increasing threshold gains increasing riskJonas Schiffmann, Judith Connan, Georg Salomon, et al.
Human Pathology|May 7, 2013
Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrenceMaria Christina Tsourlakis, Michael Schoop, Christoph Plass, et al.
Pageof 36